|
Abstract To investigate the effect of recombinant human interferon-α2b (rhIFN-α2b) combined with sodium citrate sodium chloride for treating cervical human papillomavirus (HPV) continuous infection of the women. Methods: 134 women with cervical HPV infection were randomly divided into study group and control group (67 cases in each group) by random number table from March 2016 to October 2018. The women in the two groups were treated with rhIFN-α2b for 3 months, and the women in the study group were treated with citrate sodium chloride additionally. The Th1/Th2 cytokines level, HPV-DNA load, cervical inflammatory score, and clinical efficacy of the women in the two groups were compared before and after treatment. Results: After treatment, the serum levels of IL-2 (75.05±8.96 pg/ml), IFN-γ(1.03±0.26 pg/ml), IL-10 (23.07±4.77 pg/ml), IL-4 (36.09±6.36 pg/ml), HPV-DNA load (1.60±0.63 log10 copies/l), and cervical inflammatory score (1.3±0.6 points) of the women in the study group were significant lower than those of the women in the control group, and the clinical efficacy of the women in the study group was significant better (all P＜0.05). Conclusion: The effect of rhIFN-α2b combined with sodium citrate sodium chloride for treating cervical HPV continuous infection is superior to that of rhIFN-α2b used only.
|
|
|
|
|
|
